The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Tau-aggregation inhibitor therapy for Alzheimer's disease
Open accessAbstract
Many trials of drugs aimed at preventing or clearing β-amyloid pathology have failed to demonstrate efficacy in recent years and further trials continue with drugs aimed at the same targets and mechanisms. The Alzheimer neurofibrillary tangle is composed of tau and the core of its constituent filaments are made of a truncated fragment from the repeat domain of tau. This truncated tau can catalyse the conversion of normal soluble tau into aggregated oligomeric and fibrillar tau which, in turn, can spread to neighbouring neurons. Tau aggregation is not a late-life process and onset of Braak stage 1 peaks in people in their late 40s or early 50s. Tau aggregation pathology at Braak stage 1 or beyond affects 50% of the population over the age of 45. The initiation of tau aggregation requires its binding to a non-specific substrate to expose a high affinity tau-tau binding domain and it is self-propagating thereafter. The initiating substrate complex is most likely formed as a consequence of a progressive loss of endosomal-lysosomal processing of neuronal proteins, particularly of membrane proteins from mitochondria. Mutations in the APP/presenilin membrane complex may simply add to the age-related endosomal-lysosomal processing failure, bringing forward, but not directly causing, the tau aggregation cascade in carriers. Methylthioninium chloride (MTC), the first identified tau aggregation inhibitor (TAI), offers an alternative to the amyloid approach. Phase 3 trials are underway with a novel stabilized reduced form of methylthioninium (LMTX) that has improved tolerability and absorption.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
What is cognitive reserve? Theory and research application of the reserve concept
STERN, Y. (2002) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617702813248 · Cited by 3,951
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Transmission and spreading of tauopathy in transgenic mouse brain
Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.
Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38495-8 · Cited by 1,778
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Uber eine eigenartige Erkrankung der Hirnrinde
Alzheimer, A. (1907) · Medical Entomology and Zoology · Cited by 1,503
A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Propagation of Tau Misfolding from the Outside to the Inside of a Cell
Frost, B., Jacks, R. L., & Diamond, M. I. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808759200 · Cited by 1,252
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Goedert, M., Spillantini, M. G., Cairns, N. J., & Crowther, R. A. (1992) · Neuron · doi:10.1016/0896-6273(92)90117-v · Cited by 1,112
Masters, C. L., Multhaup, G., Simms, G., Pottgiesser, J., Martins, R. N., & Beyreuther, K. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb04000.x · Cited by 1,042
Goedert, M., Jakes, R., Spillantini, M. G., Hasegawa, M., Smith, M. J., & Crowther, R. A. (1996) · Nature · doi:10.1038/383550a0 · Cited by 1,036 · cited 1×
“polyanionic substrates, such as heparin or RNA have been shown to promote tau aggregation in vitro [90–92], and by products of mitochondrial clearance [93].”
BackgroundPaired Helical Filaments in Electron Microscopy of Alzheimer's Disease
KIDD, M. (1963) · Nature · doi:10.1038/197192b0 · Cited by 1,012
Wischik, C. M., Novak, M., Thøgersen, H. C., Edwards, P. C., Runswick, M. J., Jakes, R., Walker, J. E., Milstein, C., Roth, M., & Klug, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.12.4506 · Cited by 939
Self-citationUbiquitin Is a Component of Paired Helical Filaments in Alzheimer's Disease
Mori, H., Kondo, J., & Ihara, Y. (1987) · Science · doi:10.1126/science.3029875 · Cited by 843
The pathological process underlying Alzheimer’s disease in individuals under thirty
Braak, H., & Del Tredici, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0789-4 · Cited by 812
Prion-like mechanisms in neurodegenerative diseases
Frost, B., & Diamond, M. I. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2786 · Cited by 776
Perry, G., Friedman, R., Shaw, G., & Chau, V (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.9.3033 · Cited by 623
Structural characterization of the core of the paired helical filament of Alzheimer disease.
Wischik, C. M., Novak, M., Edwards, P. C., Klug, A., Tichelaar, W., & Crowther, R. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.13.4884 · Cited by 595
Self-citationSchneider, A., Biernat, J., von Bergen, M., Mandelkow, E., & Mandelkow, E.-M. (1999) · Biochemistry · doi:10.1021/bi981874p · Cited by 564
Khan, U. A., Liu, L., Provenzano, F. A., Berman, D. E., Profaci, C. P., Sloan, R., Mayeux, R., Duff, K. E., & Small, S. A. (2014) · Nature Neuroscience · doi:10.1038/nn.3606 · Cited by 561
Kampers, T., Friedhoff, P., Biernat, J., Mandelkow, E.-M., & Mandelkow, E. (1996) · FEBS Letters · doi:10.1016/s0014-5793(96)01386-5 · Cited by 548
Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.
Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., & Harrington, C. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11213 · Cited by 547
Self-citationInhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins
Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S.-I., Iwatsubo, T., Goedert, M., & Hasegawa, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m408714200 · Cited by 540
Inhibition of nitric oxide synthesis by methylene blue
Mayer, B., Brunner, F., & Schmidt, K. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90072-5 · Cited by 535
Phosphorylated Tau Protein Is Integrated into Paired Helical Filaments in Alzheimer's Disease1
IHARA, Y., NUKINA, N., MIURA, R., & OGAWARA, M. (1986) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a135662 · Cited by 532
Anderton, B. H., Breinburg, D., Downes, M. J., Green, P. J., Tomlinson, B. E., Ulrich, J., Wood, J. N., & Kahn, J. (1982) · Nature · doi:10.1038/298084a0 · Cited by 531
Doody, R. S., Gavrilova, S. I., Sano, M., Thomas, R. G., Aisen, P. S., Bachurin, S. O., Seely, L., & Hung, D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 460
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431 · cited 1×
“NCT01760005 [16]”
Pérez, M., Valpuesta, J. M., Medina, M., Montejo de Garcini, E., & Avila, J. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67031183.x · Cited by 411
Grundke-Iqbal, I., Iqbal, K., Tung, Y.-C., Quinlan, M., Wisniewski, H., & Binder, L. (1987) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198701030-00020 · Cited by 410
Coric, V., van Dyck, C. H., Salloway, S., Andreasen, N., Brody, M., Richter, R. W., Soininen, H., Thein, S., Shiovitz, T., Pilcher, G., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.2194 · Cited by 374
Amyloid Imaging with18F-Florbetaben in Alzheimer Disease and Other Dementias
Villemagne, V. L., Ong, K., Mulligan, R. S., Holl, G., Pejoska, S., Jones, G., O'Keefe, G., Ackerman, U., Tochon-Danguy, H., Chan, J. G., et al. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.089730 · Cited by 372
Fleisher, A. S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.150 · Cited by 364
Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study
del Ser, T., Steinwachs, K. C., Gertz, H. J., Andrés, M. V., Gómez-Carrillo, B., Medina, M., Vericat, J. A., Redondo, P., Fleet, D., & León, T. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120805 · Cited by 329 · cited 1×
“Noscira tested the GSK 3b inhibitor tideglusib, but found no efficacy in PSP (NCT01049399; 12mo 146 subjects) [41].”
MethodBancher, C., Braak, H., Fischer, P., & Jellinger, K. A. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90590-h · Cited by 318
Congdon, E. E., Wu, J. W., Myeku, N., Figueroa, Y. H., Herman, M., Marinec, P. S., Gestwicki, J. E., Dickey, C. A., Yu, W. H., & Duff, K. E. (2012) · Autophagy · doi:10.4161/auto.19048 · Cited by 297
Aisen, P. S., Gauthier, S., Ferris, S. H., Saumier, D., Haine, D., Garceau, D., Duong, A., Suhy, J., Oh, J., Lau, W. C., et al. (2011) · Archives of Medical Science · doi:10.5114/aoms.2011.20612 · Cited by 295
Wilcock, G. K., Black, S. E., Hendrix, S. B., Zavitz, K. H., Swabb, E. A., & Laughlin, M. A. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70090-5 · Cited by 290
Ramsay, R. R., Dunford, C., & Gillman, P. K. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707430 · Cited by 276
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182309fa5 · Cited by 258 · cited 1×
“Therapeutics 2 Failed (18mo, 353) Amyloid-lowering agent NCT00568776 [14]”
Clarifying lysosomal storage diseases
Schultz, M. L., Tecedor, L., Chang, M., & Davidson, B. L. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.05.006 · Cited by 245
A phase II trial of huperzine A in mild to moderate Alzheimer disease
Rafii, M. S., Walsh, S., Little, J. T., Behan, K., Reynolds, B., Ward, C., Jin, S., Thomas, R., Aisen, P. S., & Study, F. T. A. D. C. (2011) · Neurology · doi:10.1212/wnl.0b013e318216eb7b · Cited by 240
Memory and mental status correlates of modified Braak staging
Grober, E., Dickson, D., Sliwinski, M. J., Buschke, H., Katz, M., Crystal, H., & Lipton, R. B. (1999) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00063-9 · Cited by 236
Subunit structure of paired helical filaments in Alzheimer's disease.
Wischik, C. M., Crowther, R. A., Stewart, M., & Roth, M. (1985) · The Journal of cell biology · doi:10.1083/jcb.100.6.1905 · Cited by 230
Self-citationChemical Manipulation of Hsp70 ATPase Activity Regulates Tau Stability
Jinwal, U. K., Miyata, Y., Koren, J., Jones, J. R., Trotter, J. H., Chang, L., O'Leary, J., Morgan, D., Lee, D. C., Shults, C. L., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3345-09.2009 · Cited by 228
Ohm, T. G., Müller, H., Braak, H., & Bohl, J. (1995) · Neuroscience · doi:10.1016/0306-4522(95)90397-p · Cited by 222
Methylene Blue Inhibits Amyloid Aβ Oligomerization by Promoting Fibrillization
Necula, M., Breydo, L., Milton, S., Kayed, R., van der Veer, W. E., Tone, P., & Glabe, C. G. (2007) · Biochemistry · doi:10.1021/bi700411k · Cited by 213
Mullane, K., & Williams, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 213
Brion, J., Passareiro, H., Nunez, J., & Durand, J. F. (1985) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · Cited by 197
The Ubiquitin-Proteasome System and the Autophagic-Lysosomal System in Alzheimer Disease
Ihara, Y., Morishima-Kawashima, M., & Nixon, R. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006361 · Cited by 190
Adverse Effects of Methylene Blue on the Central Nervous System
Vutskits, L., Briner, A., Klauser, P., Gascon, E., Dayer, A. G., Kiss, J. Z., Muller, D., Licker, M. J., & Morel, D. R. (2008) · Anesthesiology · doi:10.1097/aln.0b013e3181684be4 · Cited by 187
Mukaetova-Ladinska, E. B., Garcia-Siera, F., Hurt, J., Gertz, H. J., Xuereb, J. H., Hills, R., Brayne, C., Huppert, F. A., Paykel, E. S., McGee, M., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64573-7 · Cited by 187
Self-citationMartone, R. L., Zhou, H., Atchison, K. P., Comery, T. A., Xu, J. Z., Huang, X., Gong, X., Jin, M., Kreft, A. F., Harrison, B. L., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.152975 · Cited by 179
O'Leary, J. C., Li, Q., Marinec, P., Blair, L. J., Congdon, E. E., Johnson, A. G., Jinwal, U. K., Koren, J., Jones, J. R., Kraft, C., et al. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-45 · Cited by 176
Jobst, K. A., Smith, A. D., Barker, C. S., Wear, A., King, E. M., Smith, A., Anslow, P. A., Molyneux, A. J., Shepstone, B. J., & Soper, N. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.190 · Cited by 163
Mechanistic Basis of Phenothiazine‐Driven Inhibition of Tau Aggregation
Akoury, E., Pickhardt, M., Gajda, M. J., Biernat, J., Mandelkow�, E., & Zweckstetter, M. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208290 · Cited by 160
Modeling the Relation Between Neurofibrillary Tangles and Intellectual Status
Duyckaerts, C. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)80306-5 · Cited by 150
Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.03.007 · Cited by 147
Yen, S. H., Dickson, D. W., Crowe, A., Butler, M., & Shelanski, M. L. (1987) · PubMed · Cited by 146
Harrington, C. R., Louwagie, J., Rossau, R., Vanmechelen, E., Perry, R. H., Perry, E. K., Xuereb, J. H., Roth, M., & Wischik, C. M. (1994) · PubMed · doi:10.25405/ncl.34087548 · Cited by 145
Self-citation“Prion‐Like” Templated Misfolding in Tauopathies
Clavaguera, F., Lavenir, I., Falcon, B., Frank, S., Goedert, M., & Tolnay, M. (2013) · Brain Pathology · doi:10.1111/bpa.12044 · Cited by 141
Bancher, C., Jellinger, K., Lassmann, H., Fischer, P., & Leblhuber, F. (1996) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02189115 · Cited by 130
Wischik, C. M., Bentham, P., Wischik, D., & Seng, K. M. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.438 · Cited by 118
Self-citationMethylene blue and dimebon inhibit aggregation of TDP‐43 in cellular models
Yamashita, M., Nonaka, T., Arai, T., Kametani, F., Buchman, V. L., Ninkina, N. N., Бачурин, С. О., Akiyama, H., Goedert, M., & Hasegawa, M. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.06.042 · Cited by 116
Crowe, A., Huang, W., Ballatore, C., Johnson, R. L., Hogan, A. L., Huang, R., Wichterman, J., McCoy, J. G., Huryn, D. M., Auld, D. S., et al. (2009) · Biochemistry · doi:10.1021/bi9006435 · Cited by 107
Stimulation of respiration by methylene blue in rat liver mitochondria
Visarius, T. M., Stucki, J. W., & Lauterburg, B. H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00767-9 · Cited by 104
Maccecchini, M. L., Chang, M. Y., Pan, C., John, V., Zetterberg, H., & Greig, N. H. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302589 · Cited by 102
Morozova, O. A., March, Z. M., Robinson, A. S., & Colby, D. W. (2013) · Biochemistry · doi:10.1021/bi400866w · Cited by 95
Yen, S.-H. C., Gaskin, F., & Fu, S. M. (1983) · PubMed · Cited by 84
Tau pathology in children and young adults: can you still be unconditionally baptist?
Duyckaerts, C. J. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0794-7 · Cited by 84
García‐Sierra, F., Wischik, C. M., Harrington, C. R., Luna‐Muñoz, J., & Mena, R. (2001) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(01)00096-5 · Cited by 81
Self-citationA controlled trial of methylene blue in severe depressive illness
Naylor, G. J., Smith, A. H. W., & Connelly, P. (1987) · Biological Psychiatry · doi:10.1016/0006-3223(87)90194-6 · Cited by 75
Serial brain MRI at 3–6 month intervals as a surrogate marker for Alzheimer's disease
Bradley, K. M., Bydder, G. M., Budge, M. M., Hajnal, J. V., White, S., Ripley, B. D., & Smith, A. D. (2002) · British Journal of Radiology · doi:10.1259/bjr.75.894.750506 · Cited by 72
Wischik, C. M., Edwards, P. C., Lai, R. Y. K., Gertz, H. N.-J., Xuereb, J. H., Paykel, E. S., Brayne, C., Huppert, F. A., Mukaetova‐Ladinska, E. B., Mena, R., et al. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)97327-d · Cited by 70
Self-citation18F-florbetaben Aβ imaging in mild cognitive impairment
Ong, K. T., Villemagne, V. L., Bahar‐Fuchs, A., Lamb, F., Chételat, G., Raniga, P., Mulligan, R. S., Salvado, O., Pütz, B., Roth, K. S., et al. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt158 · Cited by 68
Sequestration of tau by granulovacuolar degeneration in Alzheimer's disease.
Bondareff, W., Wischik, C. M., Novák, M., & Roth, M. (1991) · PubMed · Cited by 64
Self-citationThe interaction between methylene blue and the cholinergic system
Pfaffendorf, M., Bruning, T. A., Batink, H. D., & van Zwieten, P. A. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701355 · Cited by 62
Narsapur (1983) · doi:10.1016/0165-0327(83)90008-3 · Cited by 59
Decreased cerebral blood flow and prognosis of Alzheimer's disease: A multicenter HMPAO-SPECT study
Nishimura, T., Hashikawa, K., Fukuyama, H., Kubota, T., Kitamura, S., Matsuda, H., Hanyu, H., Nabatame, H., Oku, N., Tanabe, H., et al. (2007) · Annals of Nuclear Medicine · doi:10.1007/bf03033995 · Cited by 46
Novel Types of Frontotemporal Lobar Degeneration: Beyond Tau and TDP-43
Mackenzie, I. R., Neumann, M., Cairns, N. J., Muñoz, D. G., & Isaacs, A. M. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9551-1 · Cited by 43
Dickey, C. A., Ash, P. E. A., Klosak, N., Lee, C. W., Petrucelli, L., Hutton, M. L., & Eckman, C. B. (2006) · Molecular Neurodegeneration · doi:10.1186/1750-1326-1-6 · Cited by 42
Examination of phosphorylated tau protein as a PHF-precursor at early stage alzheimer's disease
Lai, R. Y. K., Gertz, H. N.-J., Wischik, D., Xuereb, J. H., Mukaetova-Ladinska, E. B., Harrington, C. R., Edwards, P. C., Mena, R., Paykel, E. S., Brayne, C., et al. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00041-c · Cited by 33
Self-citationNaylor, G. J., Smith, A. H. W., & Connelly, P. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90229-6 · Cited by 31
Neurobiology of Alzheimer's Disease
Watson, R. A. (2002) · Journal of Advanced Nursing · doi:10.1046/j.1365-2648.2002.02280_2.x · Cited by 30
Chies, A. B., Custodio, R. C., Souza, G. L. D., Corrêa, F. M. D. A., & Pereira, O. C. M. (2003) · PubMed · Cited by 12
Cited by
Bang, J., Spina, S., & Miller, B. L. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00461-4 · Cited by 1,144
Tau and neurodegenerative disease: the story so far
Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806
Šimić, G., Babić Leko, M., Wray, S., Harrington, C., Delalle, I., Jovanov-Milošević, N., Bažadona, D., Buée, L., De Silva, R., Di Giovanni, G., et al. (2016) · Biomolecules · doi:10.3390/biom6010006 · Cited by 703
Self-citationTreatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
Cummings, J. L., Tong, G., & Ballard, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180766 · Cited by 588
Amyloid β Protein and Alzheimer’s Disease: When Computer Simulations Complement Experimental Studies
Nasica-Labouze, J., Nguyen, P. H., Sterpone, F., Berthoumieu, O., Buchete, N.-V., Coté, S., De Simone, A., Doig, A. J., Faller, P., Garcia, A., et al. (2015) · Chemical Reviews · doi:10.1021/cr500638n · Cited by 584
Metadata
- Authors
- Wischik, C. M., Harrington, C. R., & Storey, J. M. D.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 88
- Issue
- 4
- Pages
- 529-539
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2092075823
- Cited by
- 262
- References
- 96
- FWCI
- 17.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.